The global viral vectors & plasmid DNA manufacturing market was estimated to be US$ 2.34 Billion in 2022 and is expected to reach US$ 10.61 Billion by 2032 at a CAGR of 16.3%.
Calcium channel blockers (CCBs) are a class of medications used primarily to treat hypertension (high blood pressure) and certain cardiovascular conditions. They work by blocking the entry of calcium ions into the smooth muscle cells of blood vessels and the heart.
By inhibiting calcium influx, CCBs relax and widen the blood vessels, which helps reduce blood pressure and improve blood flow. There are different types of calcium channel blockers, including dihydropyridines (such as amlodipine and nifedipine), phenylalkylamines (such as verapamil), and benzothiazepines (such as diltiazem). Each type acts on specific calcium channels and may have varying effects on the cardiovascular system.
Viral Vectors & Plasmid DNA Manufacturing Market Growth Drivers
Increasing demand for gene therapy is propelling the market growth
The Global Viral Vectors & Plasmid DNA Manufacturing Market is being driven by several key factors.
Firstly, there is an increasing demand for gene therapy and gene-based treatments. Gene therapy offers the potential for curative treatments for previously untreatable or difficult-to-treat diseases. For instance, Luxturna, developed by Spark Therapeutics, is an FDA-approved gene therapy that restores vision in patients with inherited retinal diseases.
Secondly, the growing prevalence of genetic disorders and chronic diseases is boosting the market. Viral vectors and plasmid DNA are used to deliver therapeutic genes to address genetic abnormalities. Zolgensma, developed by AveXis, is a gene therapy used to treat spinal muscular atrophy, a severe genetic disorder affecting muscle strength and movement.
Lastly, advancements in biotechnology and genetic engineering are contributing to the market growth. These advancements enable the production of high-quality vectors and DNA constructs with improved safety and efficiency, such as the use of viral vector pseudotyping to enhance specificity and reduce immune responses.
The combination of increasing demand for gene therapy, the prevalence of genetic disorders and chronic diseases, and advancements in biotechnology and genetic engineering is shaping the Global Viral Vectors & Plasmid DNA Manufacturing Market.
These factors are driving innovation and the development of novel therapies that hold promise for patients with previously incurable conditions. However, it is important to stay updated with the latest industry information and consult reliable sources for the most recent developments in this rapidly evolving field.
Application Segmentation of Global Viral Vectors & Plasmid DNA Manufacturing Market
Gene therapy application segment holds a significant market share in the market
Among the listed applications of viral vectors and plasmid DNA, gene therapy is considered the largest segment in terms of market size. Gene therapy involves the use of viral vectors or plasmid DNA to deliver therapeutic genes into a patient's cells, aiming to treat or cure genetic disorders, inherited diseases, or acquired conditions. The gene therapy segment holds a significant market share due to several factors.
Firstly, there is a growing demand for effective treatments for genetic disorders and previously untreatable conditions. Gene therapy offers the potential to address the root cause of these diseases by introducing functional genes or correcting genetic abnormalities.
Additionally, there has been a substantial increase in research and development activities focused on gene therapy, resulting in a pipeline of promising therapies. Numerous clinical trials and advancements in vector design and delivery techniques have contributed to the growth of this segment.
Furthermore, regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have shown increasing support and accelerated approval pathways for gene therapies, facilitating their commercialization and market expansion.
Overall, the gene therapy segment's dominance is driven by the urgent need for innovative treatments for genetic disorders, the significant research and development investments, and the favorable regulatory environment, all of which contribute to its sustained growth and market leadership.
Regional Trends of the Global Viral Vectors & Plasmid DNA Manufacturing Market
North America is a leading region in the Global Market
Geographically, Global Viral Vectors & Plasmid DNA Manufacturing Market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Following are some of the major trends in these regions –
North America: North America is a leading region in the Global Viral Vectors & Plasmid DNA Manufacturing Market, driven by robust research infrastructure, strong presence of biotech companies, and favorable regulatory frameworks supporting gene therapies and advanced therapeutics.
Europe: Europe holds a significant share in the market, with countries like Germany, UK, and France at the forefront. The region benefits from advanced healthcare systems, well-established biotech industry, and supportive regulatory policies, fostering the development and manufacturing of viral vectors and plasmid DNA.
Asia-Pacific: The Asia-Pacific region is witnessing rapid growth in the viral vectors and plasmid DNA manufacturing market. Factors such as increasing investments in biotechnology, rising adoption of advanced therapies, and expanding contract manufacturing capabilities are driving the market's growth in this region.
Middle East and Africa: The Middle East and Africa region are gradually emerging in the viral vectors and plasmid DNA manufacturing market. The region is witnessing growing investments in healthcare infrastructure, research collaborations, and initiatives to enhance biotechnology capabilities, contributing to the market's development.
South America: South America is experiencing steady growth in the viral vectors and plasmid DNA manufacturing market. The region benefits from increasing awareness of advanced therapies, expanding healthcare infrastructure, and supportive government policies promoting biotechnology and genetic research.
Key players and market strategies:
Companies operating in the Global Viral Vectors & Plasmid DNA Manufacturing Market adopt various growth strategies to expand their market presence and drive innovation.
Some of the major growth strategies include:
Strategic Partnerships and Collaborations: Companies often form strategic partnerships and collaborations to leverage complementary expertise, technologies, and resources. For instance, in 2021, Novartis entered into a collaboration with Vineti, a cell and gene therapy platform provider, to establish a technology platform for personalized CAR-T cell therapies.
Mergers and Acquisitions: Mergers and acquisitions enable companies to consolidate their position in the market, gain access to new technologies or capabilities, and expand their product portfolio. For example, Thermo Fisher Scientific acquired Brammer Bio in 2019, enhancing its capabilities in viral vector manufacturing and strengthening its position in the gene therapy market.
Capacity Expansion and Infrastructure Investments: Companies invest in expanding their manufacturing capacities and infrastructure to meet the increasing demand for viral vectors and plasmid DNA. Oxford Biomedica, a leading gene and cell therapy company, announced plans to build a new manufacturing facility in the UK to scale up production capacity for viral vectors.
Research and Development Investments: Companies allocate significant investments to research and development (R&D) activities to drive innovation and develop advanced viral vector and plasmid DNA manufacturing technologies. Bluebird bio, a gene therapy company, invests a substantial portion of its revenue in R&D to advance its product pipeline and improve manufacturing processes.
Licensing and Technology Transfer: Companies engage in licensing agreements and technology transfers to gain access to patented technologies or manufacturing platforms. UniQure, a gene therapy company, entered into a licensing agreement with CSL Behring to develop and commercialize gene therapies for hemophilia B, leveraging UniQure's proprietary manufacturing technology.
BioNTech SE (Germany), bluebird bio, Inc. (United States), Brammer Bio (United States), FUJIFILM Diosynth Biotechnologies (Japan), Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania (United States), General Electric Company (GE) (United States), Lonza Group Ltd. (Switzerland), Novartis AG (Switzerland), Oxford Biomedica plc (United Kingdom), Pfizer Inc. (United States), Sanofi S.A. (France), Spark Therapeutics, Inc. (United States), Thermo Fisher Scientific Inc. (United States), uniQure N.V. (Netherlands), WuXi AppTec (China) and many more.
Global Viral Vectors & Plasmid DNA Manufacturing Market Segmentation:
Based on Vector Type:
- Viral Vectors:
- Retroviruses
- Lentiviruses
- Adenoviruses
- Adeno-associated viruses (AAV)
- Other viral vectors (e.g., Herpes simplex virus, Vaccinia virus)
- Plasmid DNA
Based on Application:
- Gene Therapy
- Vaccinology
- Cell Therapy
- Immunotherapy
- Others
Based on Disease Indication:
- Genetic Disorders
- Cancer
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Others
Based on End User:
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Academic and Research Institutes
- Hospitals and Clinics
Based on Manufacturing Method:
- In-house Manufacturing
- Outsourced Manufacturing
Based on Region
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
